Literature DB >> 9802636

Respiratory syncytial virus vaccines.

R A Karron1, D M Ambrosino.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9802636     DOI： 10.1097/00006454-199810000-00014

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN： 0891-3668            Impact factor:   2.129


× No keyword cloud information.
  5 in total

1.  Hospitalisation for RSV infection in ex-preterm infants-implications for use of RSV immune globulin.

Authors:  M Thomas; A Bedford-Russell; M Sharland
Journal:  Arch Dis Child       Date:  2000-08       Impact factor: 3.791

2.  Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3.

Authors:  A C Schmidt; J M McAuliffe; B R Murphy; P L Collins
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

Review 3.  Active immunization in the United States: developments over the past decade.

Authors:  P H Dennehy
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

4.  Mucosal immunization of rhesus monkeys against respiratory syncytial virus subgroups A and B and human parainfluenza virus type 3 by using a live cDNA-derived vaccine based on a host range-attenuated bovine parainfluenza virus type 3 vector backbone.

Authors:  Alexander C Schmidt; Daniel R Wenzke; Josephine M McAuliffe; Marisa St Claire; William R Elkins; Brian R Murphy; Peter L Collins
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

5.  The stability of human respiratory syncytial virus is enhanced by incorporation of the baculovirus GP64 protein.

Authors:  Patricia Sastre; Antonius G P Oomens; Gail W Wertz
Journal:  Vaccine       Date:  2007-05-07       Impact factor: 3.641
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.